Literature DB >> 24798496

Long-term control of viral replication in a Group O, human immunodeficiency virus type 1-infected individual.

Robert W Buckheit1, Stephen B Sexauer, Ahmad R Sedaghat, Claus O Wilke, Oliver Laeyendecker, Christie R Basseth, Joel N Blankson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24798496      PMCID： PMC4046214          DOI： 10.1089/aid.2014.0054

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  13 in total

1.  Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses.

Authors:  D Descamps; G Collin; F Letourneur; C Apetrei; F Damond; I Loussert-Ajaka; F Simon; S Saragosti; F Brun-Vézinet
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  HIV infections in northwestern Cameroon: identification of HIV type 1 group O and dual HIV type 1 group M and group O infections.

Authors:  Julie Yamaguchi; Pierre Bodelle; Ana S Vallari; Ruthie Coffey; Carole P McArthur; Gerald Schochetman; Sushil G Devare; Catherine A Brennan
Journal:  AIDS Res Hum Retroviruses       Date:  2004-09       Impact factor: 2.205

3.  Evaluation of the Abbott investigational use only realtime HIV-1 assay and comparison to the Roche Amplicor HIV-1 monitor test, version 1.5.

Authors:  Michael T Pyne; Eric Q Konnick; Amit Phansalkar; David R Hillyard
Journal:  J Mol Diagn       Date:  2009-05-21       Impact factor: 5.568

4.  A new human immunodeficiency virus derived from gorillas.

Authors:  Jean-Christophe Plantier; Marie Leoz; Jonathan E Dickerson; Fabienne De Oliveira; François Cordonnier; Véronique Lemée; Florence Damond; David L Robertson; François Simon
Journal:  Nat Med       Date:  2009-08-02       Impact factor: 53.440

Review 5.  Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control.

Authors:  Adam R Hersperger; Stephen A Migueles; Michael R Betts; Mark Connors
Journal:  Curr Opin HIV AIDS       Date:  2011-05       Impact factor: 4.283

6.  Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors.

Authors:  Denis M Tebit; Michael Lobritz; Matthew Lalonde; Taina Immonen; Kamlendra Singh; Stefanos Sarafianos; Ottmar Herchenröder; Hans-Georg Kräusslich; Eric J Arts
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

7.  Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes.

Authors:  F Gao; E Bailes; D L Robertson; Y Chen; C M Rodenburg; S F Michael; L B Cummins; L O Arthur; M Peeters; G M Shaw; P M Sharp; B H Hahn
Journal:  Nature       Date:  1999-02-04       Impact factor: 49.962

8.  T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors.

Authors:  Ahmad R Sedaghat; Darius A Rastegar; Karen A O'Connell; Jason B Dinoso; Claus O Wilke; Joel N Blankson
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

Review 9.  The implications of viral reservoirs on the elite control of HIV-1 infection.

Authors:  Robert W Buckheit; Maria Salgado; Karen O Martins; Joel N Blankson
Journal:  Cell Mol Life Sci       Date:  2012-08-04       Impact factor: 9.261

10.  Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon.

Authors:  Avelin F Aghokeng; Eitel Mpoudi-Ngole; Henriette Dimodi; Arrah Atem-Tambe; Marcel Tongo; Christelle Butel; Eric Delaporte; Martine Peeters
Journal:  PLoS One       Date:  2009-11-06       Impact factor: 3.240
View more
  1 in total

1.  Differential Control of BST2 Restriction and Plasmacytoid Dendritic Cell Antiviral Response by Antagonists Encoded by HIV-1 Group M and O Strains.

Authors:  Mariana G Bego; Lijun Cong; Katharina Mack; Frank Kirchhoff; Éric A Cohen
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.